Global Leukaemia Therapeutics Market

Description

Leukaemia is the cancer of blood cells. Blood cells originate from HSCs, hematopoietic stem cells, in the bone marrow. Thereafter they undergo maturation process called hematopoiesis. Multipotent hematopoietic stem cells often undergo a process of differentiation while in maturation stage to give rise to progenitor cells of myeloid and lymphoid origin. These Myeloid cells include neutrophils, basophils, monocytes, macrophages, erythrocytes, dendritic cells, eosinophils, and megakaryocytes or platelets. While, Lymphoid cells include B cells, T cells and natural killer cells.

Normally, the blood forming cells in the bone marrow produce leukocytes, that protects against viruses and bacteria. If these leukocytes get damaged and if they are left untreated they get accumulated in the body and invade in other parts like liver, spleen and central nervous system, hence damaging the entire body. The main reasons causing leukaemia are ionizing radiation, smoking, prior chemotherapy and Down syndrome.

Market Dynamics

Recently in 2016, Global Leukaemia Therapeutics Market was valued at nearly USD 9.44 billion and is expected to grow at a CAGR of 4.1% between 2017 and 2022, accounting to market worth USD 11.97 billion by end of 2022.
Global Leukaemia Therapeutics market is majorly driven by the growing number of incidences of target disease across the globe. Also, development of novel agents, advancements in technology and combination therapy with reduced side effects and better survival conditions are some other key factors that drives the Leukaemia Therapeutics Market.
However, the high cost of combination therapies and clinical trials coupled with post-treatment complications, adverse events and side effects are the major constraints that limit the growth of the market.

Nevertheless, initiatives like increasing focus on healthcare and personalized medicine along with huge govt. investment & R&D in anti-leukaemia therapeutics research are sure short to boost the market growth in the near future.

Market Segmentation

Global Leukaemia Therapeutics Market can be segmented as follows :

Segmentation by Type

• Chronic leukaemia

• Chronic myeloid leukaemia

• Chronic lymphatic leukaemia

• Acute leukaemia

• Acute myeloid leukaemia

• Acute lymphatic leukaemia

Segmentation by Therapy

• Biological Therapy

• Radiation therapy

• Chemotherapy

• Targeted therapy

Regional/Geographic Analysis

Europe, North America, Latin America, Asia-Pacific, Middle East & Africa are key market segments of global Leukaemia Therapeutics. North America is the leading region and is anticipated to remain one in the near future, over the forecast period. Demand for leukaemia therapeutics was highest in North America especially in the U.S attributing to increasing geriatric population and increased number of cases. While, Asia Pacific region along with Middle East, Africa and Latin America is expected to grow at moderate pace.

Key Players

The key players in global leukaemia therapeutics market include F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb, Amgen, Pfizer, Teva Pharmaceuticals, Novartis International AG., GlaxoSmithKline plc., Genzyme Corporation, AbbVie Inc. and others.

The report contains comprehensive analysis on:

• Global Leukaemia Therapeutics Market Dynamics – growth drivers, restraints and opportunities

• Global Leukaemia Therapeutics Market Segment – By method and by product

• Global Leukaemia Therapeutics Market Regional Analysis

• Key Players in the Global Leukaemia Therapeutics Market

Related Products:

Global Leukaemia Therapeutics Market

Global Dermatological Therapeutics basically caters to three problems viz. cosmetics, skin cancer and general conditions such as Acne. Current analysis of the market shows huge demand and a lesser supply, and therefore the market is and is going to undergo impressive growth in the years to come. Also, the investments and consolidation is majorly carried out by the private sector and right now, the market is fragmented among few players that will remain more or less the same. Also, the patents...

Global Leukaemia Therapeutics Market

In today's world, with the growing urbanization, air pollution is one of the major reasons for concern regarding people's health concerns. One of the major diseases that is getting prevalence, mostly among the developed countries is lung cancer. This is giving rise to the therapeutics market for lung cancer. Also, the developing markets are having increasing concerns about this disease and therefore, the therapeutics market is expected to develop rapidly. End-User/Technology The end-use...

Global Leukaemia Therapeutics Market

Solid tumor therapeutics are those pharmaceuticals which specifically treat various types of cancers such as breast cancer, lung cancer, prostate cancer, colorectal cancer, cervical cancer and others. Solid tumors are an abnormal mass of tissue that usually does not contain cysts or liquid areas. They are of two types, namely benign and malignant. The treatment of solid tumors requires synchronized actions of many healthcare professionals, such as surgeons, radiation specialists, oncologists,...

Global Leukaemia Therapeutics Market

The market was valued at USD 11 billion in 2017 and is projected to reach USD 51 billion by 2022, at a CAGR of 29% during the forecast period. The increasing prevalence of chronic diseases such as cancer and HIV/AIDS are the major reasons driving the market growth. These medicines helps to strengthen the immune response of the body against specific diseases. However every medicine need to be approved by FDA. Increasing cases of chronic diseases and need for effective treatment is acting as ke...

Global Leukaemia Therapeutics Market

A urinary tract infection (UTI) is considered as one of the most common types of infection and is caused by microbes such as bacteria overcoming the body's defenses in the urinary tract. The urinary tract can be divided into the upper urinary tract consisting of kidneys and the ureters and the lower urinary tract that consists of the bladder and the urethra. The common symptoms include a frequent and strong urge to urinate along with a painful and burning sensation when urinating, strong odou...

Global Leukaemia Therapeutics Market

Introduction One of the leading infectious disease, HIV is taking a huge death toll across the globe, surpassing malaria and TB. Therapeutic HIV vaccines are designed for patients who have HIV with the aim to improve the body’s immune response to the disease. Preventive HIV vaccine is given to people who are not suffering from HIV, with the aim of preventing HIV infection in the future. Currently, there are no therapeutic and preventive HIV vaccines approved by the Food and Drug Administra...

Global Leukaemia Therapeutics Market

$3,850.0

Industry Analysis, Forecasts and Opportunity Assessment (2017-2022)

  • Market Trends, Dynamics and Regulatory Framework
  • Regional and Cross-segment Sales Figures
  • Extensive Industry Structure Coverage

Sample Report Request Customisation

Clear
SKU: N/A Category:

    
    
    	
×
Sample Report
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. You may contact us at any time to opt-out. Please tick here to receive these communications.
×
Report Customisation
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. You may contact us at any time to opt-out. Please tick here to receive these communications.
×